DRUG SHOWS NEW PROMISE FOR BREAST CANCER TREATMENT
Professor Wayne Tilley from the University of Adelaide has contributed critical research findings that led to the new clinical trial which tests enobosarm and other AR (androgen receptor) modulator drugs as treatment options for women with ER-positive breast cancer. Enobosarm and other similar drugs work by stimulating hormone receptors like steroids but with reduced side effects.
By reducing side effects, Enobosarm may spare patients from the potentially debilitating side effects often associated with treatments for hormone-related breast cancer, and therefore improve their well-being.
“We have been advocates for enobosarm and similar drugs because they not only have the potential to prolong life, but they have the potential to make patients feel better while on therapy,” Professor Tilley explained. “This reduction in negative side effects is because the drugs promote bone, muscle and brain health.”
“Funding for this pilot study by the NBCF has provided evidence to justify continuing this avenue of research and to translate it into clinical practice. Thank you for supporting our efforts to provide effective and very tolerable means to treat this awful disease.”
Professor Wayne Tilley, NBCF-funded researcher
Lucija was diagnosed with ER-positive breast cancer in 2013, just days after Christmas. She had a host of treatments, including a lumpectomy, hormone therapy, chemotherapy and radiotherapy.
Lucija remains passionate about highlighting the importance of breast cancer research for future generations impacted by the disease.
“The incredible advances we have seen in treatment due to research gives each of us a feeling of hope that zero deaths from breast cancer is just around the corner,” she says.